Business
RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting
MOUNTAIN VIEW, Calif., March 28, 2025--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, announced today that a new human pharmacokinetic (PK) data abstract was presented at the Society of Surgical Oncology (SSO) 2025 Annual Meeting on March 27 – 29, 2025 in Tampa, FL: ePoster P379.
About this update from Renovorx, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/2cb20d6c319c5b2d4d11c07207389537"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pJWgNRQUO1mHW_BpQ_h3zg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/2cb20d6c319c5b2d4d11c07207389537","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/5baQTJMfLicZ7kJzULBdYg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/2cb20d6c319c5b2d4d11c07207389537","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Data supports the novel Trans-Arterial Micro-Perfusion (TAMPTM) therapy platform for targeted chemotherapy delivery for the potential to minimize a therapy’s toxicities versus systemic intravenous therapies","length":206,"tagName":"p","attribs":{}},{"type":"text","content":"Data shows localized, intra-arterial delivery of gemcitabine with FDA-cleared RenovoCath® device (known as IAG) resulted in lower systemic levels of drug compared to intravenous delivery of gemcitabine","length":201,"tagName":"p","attribs":{}},{"type":"text","content":"MOUNTAIN VIEW, Calif., March 28, 2025--(BUSINESS WIRE)--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, announced today that a new human pharmacokinetic (PK) data abstract was presented at the Society of Surgical Oncology (SSO) 2025 Annual Meeting on March 27 – 29, 2025 in Tampa, FL: ePoster P379.","length":481,"tagName":"p"},{"type":"text","content":"The abstract provides new human PK data relevant to RenovoRx’s proprietary Trans-Arterial Micro-Perfusion (TAMPTM) therapy platform. TAMP is key to the Company’s Phase III investigational drug-device combination oncology product candidate (intra-arterial gemcitabine, with RenovoCath, known as IAG) and is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapies. RenovoRx’s novel approach ...